Liquid Biopsy in the Management of Breast Cancer Patients: Where Are We Now and Where Are We Going
Abstract
:1. Introduction
1.1. ctDNA
1.2. CTCs
1.3. ctDNA and CTC in BC
1.4. ctDNA and CTC in MBC
2. Where Are We Now
2.1. EBC
2.1.1. ctDNA
2.1.2. CTCs
2.2. MBC
2.2.1. ctDNA
2.2.2. CTCs
Prognostic Relevance of CTCs
CTCs for Therapy Monitoring
Selection of Therapy CTC-Driven
CTCs and ctDNA
3. Where Are We Going
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Silveira, A.B.; Bidard, F.-C.; Tanguy, M.-L.; Girard, E.; Trédan, O.; Dubot, C.; Jacot, W.; Goncalves, A.; Debled, M.; Levy, C.; et al. Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer. Npj Breast Cancer 2021, 7, 115. [Google Scholar] [CrossRef] [PubMed]
- Ramos-Medina, R.; López-Tarruella, S.; del Monte-Millán, M.; Massarrah, T.; Martín, M. Technical Challenges for CTC Implementation in Breast Cancer. Cancers 2021, 13, 4619. [Google Scholar] [CrossRef]
- Richard, V.; Davey, M.G.; Annuk, H.; Miller, N.; Kerin, M.J. The double agents in liquid biopsy: Promoter and informant biomarkers of early metastases in breast cancer. Mol. Cancer 2022, 21, 95. [Google Scholar] [CrossRef]
- Heitzer, E.; Haque, I.S.; Roberts, C.E.S.; Speicher, M.R. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat. Rev. Genet. 2019, 20, 71–88. [Google Scholar] [CrossRef] [PubMed]
- Keup, C.; Suryaprakash, V.; Storbeck, M.; Hoffmann, O.; Kimmig, R.; Kasimir-Bauer, S. Longitudinal Multi-Parametric Liquid Biopsy Approach Identifies Unique Features of Circulating Tumor Cell, Extracellular Vesicle, and Cell-Free DNA Characterization for Disease Monitoring in Metastatic Breast Cancer Patients. Cells 2021, 10, 212. [Google Scholar] [CrossRef]
- Venesio, T.; Siravegna, G.; Bardelli, A.; Sapino, A. Liquid Biopsies for Monitoring Temporal Genomic Heterogeneity in Breast and Colon Cancers. Pathobiology 2017, 85, 146–154. [Google Scholar] [CrossRef] [PubMed]
- Martelotto, L.G.; Ng, C.K.Y.; Piscuoglio, S.; Weigelt, B.; Reis-Filho, J.S. Breast cancer intra-tumor heterogeneity. Breast Cancer Res. 2014, 16, 210. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ivanova, E.; Ward, A.; Wiegmans, A.P.; Richard, D.J. Circulating Tumor Cells in Metastatic Breast Cancer: From Genome Instability to Metastasis. Front. Mol. Biosci. 2020, 7, 134. [Google Scholar] [CrossRef] [PubMed]
- De Rubis, G.; Krishnan, S.R.; Bebawy, M. Liquid Biopsies in Cancer Diagnosis, Monitoring, and Prognosis. Trends Pharmacol. Sci. 2019, 40, 172–186. [Google Scholar] [CrossRef] [PubMed]
- Jahr, S.; Hentze, H.; Englisch, S.; Hardt, D.; Fackelmayer, F.O.; Hesch, R.D.; Knippers, R. DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001, 61, 1659–1665. [Google Scholar]
- Chan, K.C.A.; Jiang, P.; Chan, C.W.M.; Sun, K.; Wong, J.; Hui, E.P.; Chan, S.L.; Chan, W.C.; Hui, D.S.C.; Ng, S.S.M.; et al. Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. Proc. Natl. Acad. Sci. USA 2013, 110, 18761–18768. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dawson, S.-J.; Tsui, D.W.; Murtaza, M.; Biggs, H.; Rueda, O.M.; Chin, S.-F.; Dunning, M.J.; Gale, D.; Forshew, T.; Mahler-Araujo, B.; et al. Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer. New Engl. J. Med. 2013, 368, 1199–1209. [Google Scholar] [CrossRef] [Green Version]
- Hench, I.B.; Hench, J.; Tolnay, M. Liquid Biopsy in Clinical Management of Breast, Lung, and Colorectal Cancer. Front. Med. 2018, 5, 9. [Google Scholar] [CrossRef] [PubMed]
- Pantel, K.; Alix-Panabières, C. Liquid biopsy and minimal residual disease — latest advances and implications for cure. Nat. Rev. Clin. Oncol. 2019, 16, 409–424. [Google Scholar] [CrossRef] [PubMed]
- Li, Y.; Wu, S.; Bai, F. Molecular characterization of circulating tumor cells—from bench to bedside. Semin. Cell Dev. Biol. 2018, 75, 88–97. [Google Scholar] [CrossRef]
- Kowalik, A.; Kowalewska, M.; Góźdź, S. Current approaches for avoiding the limitations of circulating tumor cells detection methods—implications for diagnosis and treatment of patients with solid tumors. Transl. Res. 2017, 185, 58–84.e15. [Google Scholar] [CrossRef] [Green Version]
- Papadaki, M.A.; Stoupis, G.; Theodoropoulos, P.A.; Mavroudis, D.; Georgoulias, V.; Agelaki, S. Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer. Mol. Cancer Ther. 2019, 18, 437–447. [Google Scholar] [CrossRef] [Green Version]
- Stoecklein, N.H.; Fischer, J.C.; Niederacher, D.; Terstappen, L.W.M.M. Challenges for CTC-based liquid biopsies: Low CTC frequency and diagnostic leukapheresis as a potential solution. Expert Rev. Mol. Diagn. 2015, 16, 147–164. [Google Scholar] [CrossRef]
- Wang, C.; Mu, Z.; Chervoneva, I.; Austin, L.; Ye, Z.; Rossi, G.; Palazzo, J.P.; Sun, C.; Abu-Khalaf, M.; Myers, R.E.; et al. Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer. Breast Cancer Res. Treat. 2016, 161, 83–94. [Google Scholar] [CrossRef]
- Hong, Y.; Fang, F.; Zhang, Q. Circulating tumor cell clusters: What we know and what we expect (Review). Int. J. Oncol. 2016, 49, 2206–2216. [Google Scholar] [CrossRef] [Green Version]
- Piñeiro, R.; Martínez-Pena, I.; López-López, R. Relevance of CTC Clusters in Breast Cancer Metastasis. Circ. Tumor Cells Breast Cancer Metastatic Dis. 2020, 1220, 93–115. [Google Scholar] [CrossRef]
- Cabel, L.; Proudhon, C.; Gortais, H.; Loirat, D.; Coussy, F.; Pierga, J.-Y.; Bidard, F.-C. Circulating tumor cells: Clinical validity and utility. Int. J. Clin. Oncol. 2017, 22, 421–430. [Google Scholar] [CrossRef]
- Mattox, A.K.; Bettegowda, C.; Zhou, S.; Papadopoulos, N.; Kinzler, K.W.; Vogelstein, B. Applications of liquid biopsies for cancer. Sci. Transl. Med. 2019, 11, eaay1984. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer statistics. CA Cancer J. Clin. 2022, 72, 7–33. [Google Scholar] [CrossRef] [PubMed]
- Prat, A.; Perou, C.M. Deconstructing the molecular portraits of breast cancer. Mol. Oncol. 2010, 5, 5–23. [Google Scholar] [CrossRef]
- Carey, L.A.; Perou, C.M.; Livasy, C.A.; Dressler, L.G.; Cowan, D.; Conway, K.; Karaca, G.; Troester, M.A.; Tse, C.K.; Edmiston, S.; et al. Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study. JAMA 2006, 295, 2492–2502. [Google Scholar] [CrossRef] [Green Version]
- Creighton, C.J. The molecular profile of luminal B breast cancer. Biol. Targets Ther. 2012, 6, 289–297. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bauer, K.R.; Brown, M.; Cress, R.D.; Parise, C.A.; Caggiano, V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California cancer Registry. Cancer 2007, 109, 1721–1728. [Google Scholar] [CrossRef]
- Bianchini, G.; Balko, J.M.; Mayer, I.A.; Sanders, M.E.; Gianni, L. Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease. Nat. Rev. Clin. Oncol. 2016, 13, 674–690. [Google Scholar] [CrossRef]
- LeVasseur, N.; Sun, J.; Gondara, L.; Diocee, R.; Speers, C.; Lohrisch, C.; Chia, S. Impact of pathologic complete response on survival after neoadjuvant chemotherapy in early-stage breast cancer: A population-based analysis. J. Cancer Res. Clin. Oncol. 2019, 146, 529–536. [Google Scholar] [CrossRef]
- Brewster, A.M.; Chavez-MacGregor, M.; Brown, P. Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. Lancet Oncol. 2014, 15, e625–e634. [Google Scholar] [CrossRef] [Green Version]
- Tsang, J.Y.; Tse, G.M. Update on triple-negative breast cancers – highlighting subtyping update and treatment implication. Histopathology 2022, 82, 17–35. [Google Scholar] [CrossRef] [PubMed]
- Zhang, M.; Rosen, J.M. Developmental Insights into Breast Cancer Intratumoral Heterogeneity. Trends Cancer 2015, 1, 242–251. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kim, C.; Gao, R.; Sei, E.; Brandt, R.; Hartman, J.; Hatschek, T.; Crosetto, N.; Foukakis, T.; Navin, N.E. Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing. Cell 2018, 173, 879–893.e13. [Google Scholar] [CrossRef] [Green Version]
- Januškevičienė, I.; Petrikaitė, V. Heterogeneity of breast cancer: The importance of interaction between different tumor cell populations. Life Sci. 2019, 239, 117009. [Google Scholar] [CrossRef]
- Fabisiewicz, A.; Szostakowska-Rodzos, M.; Zaczek, A.J.; Grzybowska, E.A. Circulating Tumor Cells in Early and Advanced Breast Cancer; Biology and Prognostic Value. Int. J. Mol. Sci. 2020, 21, 1671. [Google Scholar] [CrossRef] [Green Version]
- Hashad, D.; Sorour, A.; Ghazal, A.; Talaat, I. Free Circulating Tumor DNA as a Diagnostic Marker for Breast Cancer. J. Clin. Lab. Anal. 2012, 26, 467–472. [Google Scholar] [CrossRef]
- Koch, C.; Kuske, A.; Joosse, S.A.; Yigit, G.; Sflomos, G.; Thaler, S.; Smit, D.J.; Werner, S.; Borgmann, K.; Gärtner, S.; et al. Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity. EMBO Mol. Med. 2020, 12, e11908. [Google Scholar] [CrossRef] [PubMed]
- Banys-Paluchowski, M.; Fehm, T.; Janni, W.; Solomayer, E.-F.; Hartkopf, A. Circulating and Disseminated Tumor Cells in Breast Carcinoma. Geburtshilfe Und Frauenheilkd. 2019, 79, 1320–1327. [Google Scholar] [CrossRef]
- Woo, J.W.; Chung, Y.R.; Ahn, S.; Kang, E.; Kim, E.-K.; Kim, S.H.; Kim, J.H.; Kim, I.A.; Park, S.Y. Changes in Biomarker Status in Metastatic Breast Cancer and Their Prognostic Value. J. Breast Cancer 2019, 22, 439–452. [Google Scholar] [CrossRef] [Green Version]
- Janni, W.J.; Rack, B.; Terstappen, L.W.; Pierga, J.-Y.; Taran, F.-A.; Fehm, T.; Hall, C.; de Groot, M.R.; Bidard, F.-C.; Friedl, T.W.; et al. Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer. Clin. Cancer Res. 2016, 22, 2583–2593. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Engage Healthcare Communications, LLC. FDA Oncology Update. Am. Health Drug Benefits 2019, 12, 365–366. [Google Scholar]
- Zhang, X.; Zhao, W.; Wei, W.; You, Z.; Ou, X.; Sun, M.; Yin, Y.; Tang, X.; Zhao, Z.; Hu, C.; et al. Parallel Analyses of Somatic Mutations in Plasma Circulating Tumor DNA (ctDNA) and Matched Tumor Tissues in Early-Stage Breast Cancer. Clin. Cancer Res. 2019, 25, 6546–6553. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, Y.-H.; Hancock, B.A.; Solzak, J.P.; Brinza, D.; Scafe, C.; Miller, K.D.; Radovich, M. Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy. Npj Breast Cancer 2017, 3, 24. [Google Scholar] [CrossRef]
- Yuan, Y.; Chen, X.-S.; Liu, S.-Y.; Shen, K.-W. Accuracy of MRI in Prediction of Pathologic Complete Remission in Breast Cancer After Preoperative Therapy: A Meta-Analysis. Am. J. Roentgenol. 2010, 195, 260–268. [Google Scholar] [CrossRef]
- McDonald, B.R.; Contente-Cuomo, T.; Sammut, S.-J.; Odenheimer-Bergman, A.; Ernst, B.; Perdigones, N.; Chin, S.-F.; Farooq, M.; Mejia, R.; Cronin, P.A.; et al. Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer. Sci. Transl. Med. 2019, 11, 504. [Google Scholar] [CrossRef]
- Riethdorf, S.; Müller, V.; Zhang, L.; Rau, T.; Loibl, S.; Komor, M.; Roller, M.; Huober, J.; Fehm, T.; Schrader, I.; et al. Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial. Clin. Cancer Res. 2010, 16, 2634–2645. [Google Scholar] [CrossRef] [Green Version]
- Xenidis, N.; Ignatiadis, M.; Apostolaki, S.; Perraki, M.; Kalbakis, K.; Agelaki, S.; Stathopoulos, E.N.; Chlouverakis, G.; Lianidou, E.; Kakolyris, S.; et al. Cytokeratin-19 mRNA-Positive Circulating Tumor Cells After Adjuvant Chemotherapy in Patients With Early Breast Cancer. J. Clin. Oncol. 2009, 27, 2177–2184. [Google Scholar] [CrossRef]
- Hall, C.; Karhade, M.; Laubacher, B.; Anderson, A.; Kuerer, H.; DeSynder, S.; Lucci, A. Circulating Tumor Cells After Neoadjuvant Chemotherapy in Stage I–III Triple-Negative Breast Cancer. Ann. Surg. Oncol. 2015, 22, 552–558. [Google Scholar] [CrossRef]
- Rack, B.; Schindlbeck, C.; Jückstock, J.; Andergassen, U.; Hepp, P.; Zwingers, T.; Friedl, T.W.P.; Lorenz, R.; Tesch, H.; Fasching, P.A.; et al. Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients. Gynecol. Oncol. 2014, 106, dju273. [Google Scholar] [CrossRef]
- Huai, J.; Cao, M.; Jiang, Y.; Yang, X.; Zhu, Y.; Si, Y.; Xu, M.; Shen, C.; Han, T.; Lian, X. Evaluation of Liquid Biopsy in Patients with HER2-Positive Breast Cancer. BioMed Res. Int. 2021, 2021, 6388492. [Google Scholar] [CrossRef]
- Fehm, T.N.; Meier-Stiegen, F.; Driemel, C.; Jäger, B.; Reinhardt, F.; Naskou, J.; Franken, A.; Neubauer, H.; Neves, R.P.; van Dalum, G.; et al. Diagnostic leukapheresis for CTC analysis in breast cancer patients: CTC frequency, clinical experiences and recommendations for standardized reporting. Cytom. Part A 2018, 93, 1213–1219. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, J.; Ye, C.; Dong, J.; Cao, S.; Hu, Y.; Situ, B.; Xi, X.; Qin, S.; Xu, J.; Cai, Z.; et al. Metabolic classification of circulating tumor cells as a biomarker for metastasis and prognosis in breast cancer. J. Transl. Med. 2020, 18, 59. [Google Scholar] [CrossRef]
- Abreu, M.; Cabezas-Sainz, P.; Pereira-Veiga, T.; Falo, C.; Abalo, A.; Morilla, I.; Curiel, T.; Cueva, J.; Rodríguez, C.; Varela-Pose, V.; et al. Looking for a Better Characterization of Triple-Negative Breast Cancer by Means of Circulating Tumor Cells. J. Clin. Med. 2020, 9, 353. [Google Scholar] [CrossRef] [Green Version]
- Bettegowda, C.; Sausen, M.; Leary, R.J.; Kinde, I.; Wang, Y.; Agrawal, N.; Bartlett, B.R.; Wang, H.; Luber, B.; Alani, R.M.; et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 2014, 6, 224. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hrebien, S.; Citi, V.; Garcia-Murillas, I.; Cutts, R.; Fenwick, K.; Kozarewa, I.; McEwen, R.; Ratnayake, J.; Maudsley, R.; Carr, T.; et al. Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial. Ann. Oncol. 2019, 30, 945–952. [Google Scholar] [CrossRef] [PubMed]
- Müller, V.; Banys-Paluchowski, M.; Friedl, T.; Fasching, P.; Schneeweiss, A.; Hartkopf, A.; Wallwiener, D.; Rack, B.; Meier-Stiegen, F.; Huober, J.; et al. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. ESMO Open 2021, 6. [Google Scholar] [CrossRef] [PubMed]
- Banys-Paluchowski, M.; Fehm, T.N.; Grimm-Glang, D.; Rody, A.; Krawczyk, N. Liquid Biopsy in Metastatic Breast Cancer: Current Role of Circulating Tumor Cells and Circulating Tumor DNA. Oncol. Res. Treat. 2021, 45, 4–11. [Google Scholar] [CrossRef]
- Bidard, F.-C.; Jacot, W.; Kiavue, N.; Dureau, S.; Kadi, A.; Brain, E.; Bachelot, T.; Bourgeois, H.; Gonçalves, A.; Ladoire, S.; et al. Efficacy of Circulating Tumor Cell Count–Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer. JAMA Oncol. 2021, 7, 34–41. [Google Scholar] [CrossRef]
- Maltoni, R.; Palleschi, M.; Ravaioli, S.; Tumedei, M.M.; Rocca, A.; Melegari, E.; Altini, M.; Puccetti, M.; Manunta, S.; Bravaccini, S. Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer. Cell Transplant. 2020, 29, 100299. [Google Scholar] [CrossRef]
- Paoletti, C.; Regan, M.M.; Niman, S.M.; Dolce, E.M.; Darga, E.P.; Liu, M.C.; Marcom, P.K.; Hart, L.L.; Smith, J.W.; Tedesco, K.L.; et al. Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients. Npj Breast Cancer 2021, 7, 77. [Google Scholar] [CrossRef] [PubMed]
- Shiomi-Mouri, Y.; Kousaka, J.; Ando, T.; Tetsuka, R.; Nakano, S.; Yoshida, M.; Fujii, K.; Akizuki, M.; Imai, T.; Fukutomi, T.; et al. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer. Breast Cancer 2014, 23, 120–127. [Google Scholar] [CrossRef] [PubMed]
EBC | ||
LB Marker | Trial | Study Design |
ctDNA | NeoALTTO | Biomarker for NACT |
CTC | GeparQuattro IMENEO | Count before and after NACT |
BEVERLY-2 E5103 | Enumeration as a high-risk predictor of late recurrences | |
SUCCESS-A | Detection as a risk factor of death after the follow-up | |
MBC | ||
LB Marker | Trial | Study Design |
ctDNA | BEECH | Amount as a predictor for PFS |
CTC | DETECT | Exploitation in targeted therapy |
SWOG 0500 CirCe01 | Clinical decision tool for therapy monitoring | |
CTC and ctDNA | ELIMA | Complementary information on the genomic and transcriptomic disease complexity |
COMET | Significant prognostic value on both PFS and OS |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Mazzitelli, C.; Santini, D.; Corradini, A.G.; Zamagni, C.; Trerè, D.; Montanaro, L.; Taffurelli, M. Liquid Biopsy in the Management of Breast Cancer Patients: Where Are We Now and Where Are We Going. Diagnostics 2023, 13, 1241. https://doi.org/10.3390/diagnostics13071241
Mazzitelli C, Santini D, Corradini AG, Zamagni C, Trerè D, Montanaro L, Taffurelli M. Liquid Biopsy in the Management of Breast Cancer Patients: Where Are We Now and Where Are We Going. Diagnostics. 2023; 13(7):1241. https://doi.org/10.3390/diagnostics13071241
Chicago/Turabian StyleMazzitelli, Carlotta, Donatella Santini, Angelo Gianluca Corradini, Claudio Zamagni, Davide Trerè, Lorenzo Montanaro, and Mario Taffurelli. 2023. "Liquid Biopsy in the Management of Breast Cancer Patients: Where Are We Now and Where Are We Going" Diagnostics 13, no. 7: 1241. https://doi.org/10.3390/diagnostics13071241